Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
In Conversation: Bill Enright, Chief Executive Officer of Vaccitech By Sarah EllinwoodMay 17, 2023 Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies for [….]
Upcoming 3rd Annual BioBuzz Awards to Celebrate Winners from Maryland, Philadelphia In addition to the reception, the event will also feature several panels comprised of esteemed local key opinion leaders [….]
Today, we are excited to announce the winners of our 3rd Annual BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) and Greater Philadelphia life science communities and the individuals that make innovation happen.
We’re excited to announce this year’s finalists for the third annual 2022 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
Dozens of startups have called FastForward’s innovation hub in the 1812 Ashland building home since it opened five years ago. Now, one of the original tenants will be moving out for a good reason.
Avidea Technologies, which develops T cell immunotherapies to treat cancer and autoimmune diseases, was acquired by Vaccitech, a British drug and vaccine maker, in December 2021 for $40 million. The deal was the culmination of a lifetime of research and more recent entrepreneurial efforts by Geoffrey Lynn, Avidea’s co-founder and CEO, who attended the Johns Hopkins University School of Medicine.
“Avidea was really the vehicle for our team to advance promising therapies to patients,” he says. “From our earliest days, we always kept an open mind about how to achieve this and how we would eventually exit the company.”
Privately-held Avidea is developing next-generation T cell immunotherapies for the treatment of cancer and autoimmune diseases. The company’s immunotherapies are driven by its polymer-drug conjugate technology platform, SNAPvax, which is designed to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition. This is done so in order to enable the development of immunotherapy product candidates with tighter control over immune responses. The SNAPvax platform is designed to induce high magnitude cytotoxic T cells for treating cancer and chronic infections. It can also be configured to induce regulatory T cells for treating autoimmunity and allergies.
The ISPE Chesapeake Bay Area Chapter Mid-Atlantic Science & Technology (MAST) Virtual Showcase, hosted on May 19th, 2021, provided a platform for life science companies to discuss strategies for addressing challenges in the life science industry.
Global COVID-19 cases have been spiking in Europe and the U.S. as the predicted second wave is hitting communities hard, applying new pressure on hospital capacity and forcing local and state governments to once again tighten restrictions.
At Maryland Lifesciences’ 2020 Bio Innovation Conference, American Gene Technologies (AGT) took center stage. AGT was the virtual event’s diamond sponsor, AGT’s CEO and Founder Jeff Galvin kicked off the event with opening remarks and then hosted several panel discussions, including “Expanding Progress and Opportunities in Gene and Cell Therapy,” which was a highlight of the conference’s second day.
